ZymoGenetics Punches Bristol-Myers With Suit
On Monday, the company revealed that it had filed suit in the U.S. District Court for the District of Delaware, alleging that Bristol-Myers had violated its intellectual property.
"We have a number of patents on fusion protein technology, which we believe are being infringed by Bristol-Myers Squibb," said Bruce L.A. Carter, the president and chief executive officer of ZymoGenetics. "It is important...
To view the full article, register now.